MARKET

CSBR

CSBR

Champions
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.55
+0.48
+5.29%
After Hours: 9.55 0 0.00% 16:00 05/14 EDT
OPEN
9.03
PREV CLOSE
9.07
HIGH
9.69
LOW
9.03
VOLUME
11.45K
TURNOVER
--
52 WEEK HIGH
14.68
52 WEEK LOW
7.05
MARKET CAP
127.88M
P/E (TTM)
-88.0184
1D
5D
1M
3M
1Y
5Y
Global Humanized Mouse and Rat Model Market size estimate, share 2021, expansion plans, industry update, gross margin, revenue forecast 2025
May 10, 2021 (The Expresswire) -- Global "Humanized Mouse and Rat Model Market" covers historical and forecast data from like demand, application details and...
The Express Wire · 6d ago
Patient Derived Xenograft or PDX Models Market Share, Size, Global Development ,Growth Status, Sales Revenue, Emerging Technologies, Key Players Analysis, Opportunity Assessment and Industry Expansion Strategies 2025
May 05, 2021 (The Expresswire) -- Global Patient Derived Xenograft or PDX Models Market Research report provides detailed analysis of global market size,...
The Express Wire · 05/05 07:14
Roubaix Capital, LLC Buys Immersion Corp, Despegar. ...
GuruFocus News · 04/29 21:38
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 04/29 07:31
Patient Derived Xenograft Models Market Size, Share, Trends, Analysis and Forecast 2027
Apr 28, 2021 (Market Insight Reports) -- The Global Patient Derived Xenograft Models Market is estimated to value over USD 240 million by 2027 end and...
Market Insight Reports · 04/28 11:23
Humanized Mouse and Rat Model Industry Share, Global Industry Growth, Historical Analysis, Size, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Potential of Industry Till 2026
Apr 27, 2021 (The Expresswire) -- Global Humanized Mouse and Rat Model Market Research Report has In-Depth Collective analysis of different factors that...
The Express Wire · 04/27 09:58
The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4%
New York, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/23 11:26
PDX Model Market to Reach USD 299 million by 2026 | Key Players are JSR Corporation (Japan), WuXi AppTec (China)
Apr 20, 2021 (AB Digital via COMTEX) -- This study involved four major activities in estimating the current size of the PDX model market. Exhaustive...
ABNewswire · 04/20 22:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CSBR. Analyze the recent business situations of Champions through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CSBR stock price target is 15.00 with a high estimate of 16.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 10.19M
% Owned: 76.07%
Shares Outstanding: 13.39M
TypeInstitutionsShares
Increased
15
255.58K
New
1
713
Decreased
9
52.52K
Sold Out
2
99.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
Joel Ackerman
Chief Executive Officer/Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Director/Independent Director
David Sidransky
Director
Robert Brainin
Independent Director
Philip Breitfeld
Independent Director
Daniel Mendelson
Independent Director
Scott Tobin
No Data
About CSBR
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.

Webull offers kinds of Champions Oncology Inc stock information, including NASDAQ:CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.